Effective July 28, 2022: Texas Medicaid Preferred Drug List Updates
Date: 06/28/22
The Texas Health and Human Services (HHS) will publish the semi-annual update of the Texas Medicaid Preferred Drug List (PDF) on Thursday July 28th, 2022. The update will be based on changes presented at the Vendor Drug Program (VDP) Drug Utilization Review (DUR) Board meetings in January and April 2022. Superior HealthPlan follows the Texas Medicaid Vendor Drug Formulary and the PDL.
The tables below summarize some of the anticipated noteworthy changes from the January 2022 and April 2022 DUR meetings.
Please note: The tables are not the complete list of changes. Please reference the Texas Medicaid PDL for a complete list of recommended medications or visit DUR Board webpage on the Texas Vendor Drug website for all decisions.
Notable changes from January 2022 DUR board meeting:
PDL CLASS | DRUG | CURRENT PDL STATUS | RECOMMENDED STATUS |
|---|---|---|---|
Analgesics, Narcotics Long | Methadone Brand Sol Tablet (oral) | Non-Reviewed | Non-Preferred |
Analgesics, Narcotics Long | Tramadol ER (Ryzolt) (oral) | Non-Preferred | Preferred |
Antimigraine Agents, other | Ajovy (subcutaneous) | Non-Preferred | Preferred |
Antimigraine Agents, other | Ajovy autoinjector (subcutaneous) | Non-Preferred | Preferred |
Antimigraine Agents, other | Ajovy autoinjector 3-pk (subcutaneous) | Non-Reviewed | Preferred |
Antimigraine Agents, other | Elyxyb solution (oral) | Non-Reviewed | Non-Preferred |
Antimigraine Agents, other | Nurtec ODT (oral) | Non-Preferred | Preferred |
Antimigraine Agents, other | Qulipta (oral) | Non-Reviewed | Non-Preferred |
Antimigraine Agents, other | Trudhesa (nasal) | Non-Reviewed | Non-Preferred |
Antimigraine Agents, other | Ubrelvy (oral) | Preferred | Non-Preferred |
Glucagon Agents | Gvoke syringe (subcutaneous) | Non-Preferred | Preferred |
Glucagon Agents | Zegalogue autoinjector (subcutaneous) | Non-Preferred | Preferred |
Immunomodulators, atopic dermatitis | Elidel (topical) | Non-Preferred | Preferred |
Immunomodulators, atopic dermatitis | Opzelura (topical) | Non-Reviewed | Non-Preferred |
Immunomodulators, atopic dermatitis | Protopic (topical) | Non-Preferred | Preferred |
Neuropathic pain | Lidoderm (topical) | Non-Preferred | Preferred |
Neuropathic pain | Lyrica capsule (oral) | Non-Preferred | Preferred |
Neuropathic pain | Pregabalin capsule (AG) (oral) | Preferred | Non-Preferred |
Neuropathic pain | Pregabalin capsule (oral) | Preferred | Non-Preferred |
Potassium binders (new PDL class) | Lokelma (oral) | Non-Reviewed | Preferred |
Potassium binders (new PDL class) | Sodium polystyrene sulfonate (oral) | Non-Reviewed | Preferred |
Potassium binders (new PDL class) | Veltassa (oral) | Non-Reviewed | Non-Preferred |
Stimulants and related agents | Azstarys (oral) | Non-Reviewed | Non-Preferred |
Stimulants and related agents | Qelbree (oral) | Preferred | Non-Preferred |
Antipsychotics | Invega Hafyera (intramuscular) | Non-Reviewed | Preferred |
Antipsychotics | Lybalvi (oral) | Non-Reviewed | Non-Preferred |
Immunosuppressives, oral | Rezurock (oral) | Non-Reviewed | Non-Preferred |
Notable changes from April 2022 DUR board meeting:
PDL CLASS | DRUG | CURRENT PDL STATUS | RECOMMENDED STATUS |
|---|---|---|---|
Anticoagulants | Xarelto suspension (oral) | Non-reviewed | Non-preferred |
Antivirals, orals | Valcyte tablet (oral) | Preferred | Non-preferred |
Antivirals, orals | Valganciclovir tablet (oral) | Non-preferred | Preferred |
Erythropoiesis Stimulating Proteins | Epogen (Injection) | Non-preferred | Preferred |
Glucocorticoids, inhaled | Pulmicort Flexhaler (inhalation) | Non-preferred | Preferred |
Immune Globulins | Cytogam (intravenous) | Preferred | Non-preferred |
Immune Globulins | Gamastan S-D vial (intramuscular) | Preferred | Non-preferred |
Immune Globulins | Hepagam B (intramuscular) | Preferred | Non-preferred |
Immune Globulins | Hizentra vial (subcutaneous) | Preferred | Non-preferred |
Immune Globulins | Varizig (intramuscular) | Preferred | Non-preferred |
Immunomodulators, Asthma | Xolair syringe (subcutaneous) | Non-reviewed | Preferred |
Lincosamides/Oxazolidinones/ Streptogramins | Linezolid suspension (AG) (oral) | Preferred | Non-preferred |
Lincosamides/Oxazolidinones/ Streptogramins | Linezolid suspension (oral) | Preferred | Non-preferred |
Lipotropics, other | Colestid tablet (oral) | Non-preferred | Preferred |
Lipotropics, other | Colestipol tablet (oral) | Preferred | Non-preferred |
Lipotropics, statins | Lipitor (oral) | Non-preferred | Preferred |
Prenatal Vitamins | Citranatal B-calm (oral) | Non-preferred | Preferred |
Pulmonary Arterial Hypertension (PAH) agents, oral and inhaled | Ambrisentan (oral) | Preferred | Non-preferred |
PAH agents, oral and inhaled | Letairis (oral) | Non-preferred | Preferred |
PAH agents, oral and inhaled | Revatio tablet (oral) | Non-preferred | Preferred |
PAH agents, oral and inhaled | Sildenafil tablet (oral) | Preferred | Non-preferred |
Antiparkinson's agents | Dhivy tablet (oral) | Non-reviewed | Non-preferred |
Anticonvulsants | Eprontia solution (oral) | Preferred | Preferred |
Growth Hormone | Skytrofa cartridge (subcutaneous) | Non-reviewed | Non-preferred |
Immunomodulators, atopic dermatitis | Adbry (subcutaneous) | Non-reviewed | Non-preferred |
Ophthalmics, anti- inflammatory/immunomodulator | Tyrvaya spray (nasal) | Non-reviewed | Non-preferred |
Ophthalmics, glaucoma agents | Vuity (ophthalmic) | Non-reviewed | Non-preferred |